Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Controlled Open-label Multi-center Study to Assess the Efficacy of TCZ in Treatment of Late/Chronic Active Antibody-mediated Rejection in Kidney Transplant Recipients

NCT04561986 is registered in ClinicalTrials.gov with Vastra Gotaland Region as lead sponsor.

NCT NCT04561986
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04561986 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Controlled Open-label Multi-center Study to Assess the Efficacy of TCZ in Treatment of Late/Chronic Active Antibody-mediated Rejection in Kidney Transplant Recipients
Lead sponsor
Vastra Gotaland Region
Phase
Phase 3
Overall status
Active, not recruiting
Start date
February 1, 2022
Completion date
June 30, 2029
Enrollment
50 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

antibody-mediated rejection